India, Nov. 20 -- Shares of Capricor Therapeutics (CAPR) plunged over 70% to $1.63 in after-hours trading on Friday, following disappointing regulatory news related to its lead investigational asset, Deramiocel.

Deramiocel, proposed for the treatment of Duchenne muscular dystrophy, has been denied FDA approval yet again.

The Complete Response Letter, issued by the U.S. regulatory agency, states that the data submitted by the company do not provide sufficient evidence to establish the drug's effectiveness and identifies additional deficiencies in the clinical data.

Commenting on the setback, Capricor's Chief Executive Officer, Linda Marban, said, "We are deeply disappointed for the boys and young men living with Duchenne and their familie...